Document:

EXHIBIT 4.1

 

THIS WARRANT AND
THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”),
OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS PROVIDED HEREIN, MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED
OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER THE SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS, OR SUCH OFFER, SALE,
TRANSFER, PLEDGE OR HYPOTHECATION IS PERMITTED UNDER RULE 144 OF THE SECURITIES ACT OR IS OTHERWISE EXEMPT FROM SUCH REGISTRATION.

  

 

APOLLO MEDICAL
HOLDINGS, INC.

 

Common Stock
Purchase Warrant

 

	Warrant Number:  W-102	Issue Date: November 17, 2016

Warrant Amount: 5,000 shares

 

THIS COMMON STOCK PURCHASE
WARRANT (the “Warrant”) certifies that, for value received, Liviu Chindris, M.D., his successors and permitted
assigns (together, “Holder”) is entitled, at any time prior to 5:00 p.m., Pacific time, on November 17, 2018
(the “Expiration Date”), to purchase from Apollo Medical Holdings, Inc., a Delaware corporation (“Company”),
up to the number of fully paid and non-assessable shares (the “Shares”) of Common Stock, par value $0.001 per
share, of Company (the “Common Stock”) specified above (the “Warrant Amount”) at an exercise
price of $9.00 per Share (the “Warrant Exercise Price”) or to convert this Warrant into Shares, in each case
subject to the provisions and upon the terms and conditions set forth in this Warrant. The Warrant may be exercised as follows:

 

	 	On or after November 17, 2016	1,666 shares
	 	On or after December 17, 2016	1,667 shares
	 	On or after January 17, 2017	1,667 shares

 

This Warrant has been
issued in connection with that certain Promissory Note dated as of even date herewith, issued by Apollo Medical Management, Inc.
(“AMM”), an affiliate of the Company, as evidence of a loan in the amount of Four Hundred Thousand Dollars ($400,000)
which Holder is making to AMM.

 

 1.             EXERCISE.

 

1.1       Method
of Exercise. Holder may exercise this Warrant in whole or in part to purchase the Shares for cash by (a) delivering to Company,
in accordance with Section 5.2, a duly executed copy of a Notice of Exercise in substantially the form attached as Appendix
1 not less than sixty one (61) days prior to the date of exercise (unless the Company otherwise agrees to a shorter notice
period), and (b) causing this Warrant to be delivered to Company, in accordance with Section 5.2, as soon as reasonably
practicable on or following the date on which the Notice of Exercise is delivered to Company (but no later than within sixty one
(61) days following the date on which the Notice of Exercise is delivered to Company). Unless Holder is exercising the conversion
right provided for in Section 1.2, Holder shall, within three (3) Trading Days following the date of exercise as aforesaid,
also deliver to Company a certified or bank cashier’s check, wire transfer of immediately available funds (to an account
designated by Company), or other form of payment acceptable to Company, in the amount of the aggregate Warrant Exercise Price for
the Shares being purchased.

 

    
Signature Page to Common Stock Purchase Warrant

     

    

 

1.2       Conversion
Right. In lieu of exercising this Warrant to purchase Shares for cash in accordance with Section 1.1, Holder may, at
its option, from time to time convert this Warrant, in whole or in part and without any obligation to pay the Warrant Exercise
Price, into that number of Shares determined by dividing (x) the aggregate Fair Market Value of the Shares in respect of which
this Warrant is being converted minus the aggregate Warrant Exercise Price of such Shares by (y) the Fair Market Value of one (1)
Share. The Fair Market Value of one (1) Share shall be determined pursuant to Section 1.3. Holder may exercise such conversion
right under this Warrant in whole or in part by (a) delivering to Company, in accordance with Section 5.2, a duly executed
copy of a Notice of Exercise in substantially the form attached as Appendix 1 not less than sixty one (61) days prior to
the date of conversion (unless the Company otherwise agrees to a shorter notice period), and (b) causing this Warrant to be delivered
to Company, in accordance with Section 5.2, as soon as reasonably practicable on or following the date on which Notice of
Exercise is delivered to Company (but no later than within two (2) Trading Days following the date on which the Notice of Exercise
is delivered to Company). Any reference in this Warrant to the “exercise” of this Warrant or events to occur upon or
in connection with the exercise of this Warrant, including without limitation, all provisions of Section 2, will apply
equally and with the same equitable effect to any conversion of this Warrant even if reference is not specifically made to conversion
of this Warrant.

 

1.3       Fair
Market Value. For purposes of this Warrant, “Fair Market Value” shall mean, with respect to one (1)
Share, the price determined by the first of the following clauses that applies: (a) the average of the daily volume weighted average
trading price of the Common Stock on the Principal Trading Market for the five (5) Trading Days immediately prior to the date on
which the Notice of Exercise for exercising the conversion right under this Warrant is delivered to Company, or (b) if the Common
Stock is not so listed or quoted, as reasonably determined by the Board of Directors in good faith.

 

1.4       Delivery
of Certificate and New Warrant. Within three (3) Trading Days after Holder exercises under Section 1.1 or converts
under Section 1.2 this Warrant and, if applicable, Company receives payment of the aggregate Warrant Exercise Price, Company
shall deliver to Holder certificates (or, if consistent with Company’s practice for issuing shares of Common Stock, non-certificated
Shares represented by book-entry on the records of Company or Company’s transfer agent (the “Book-Entry Shares”))
for the Shares so acquired and, if this Warrant has not been fully exercised or converted and has not expired, a new warrant of
like tenor representing the Shares not so acquired. The Shares shall be deemed to have been issued, and Holder or any other Person
designated by Holder to be named therein shall be deemed to have become a holder of record of such Shares for all purposes as of
the date this Warrant shall have been exercised or converted. If Company fails to deliver a certificate or certificates (or, if
applicable, Book-Entry Shares) for the Shares as provided herein, in addition to any other remedy available to Holder hereunder,
at law or in equity, Holder shall have the right to rescind the exercise or conversion of this Warrant. The Holder acknowledges
and understands that any stock certificates issued hereunder and any Warrant issued in replacement of this Warrant upon its exercise,
in whole or in part, or for any other reason, shall be subject to the provisions of Section 4A of this Warrant and shall have the
legends placed thereon as appear on the first page of this Warrant.

 

    
Signature Page to Common Stock Purchase Warrant

     

    

 

1.5       Fractional
Shares. No fractional Share shall be issuable upon exercise or conversion of this Warrant, and the number of Shares
to be issues shall be rounded down to the nearest whole Share. If a fractional share interest arises upon any exercise or conversion
of this Warrant, Company shall eliminate such fractional share interest by paying Holder cash in the amount computed by multiplying
the fractional share interest by the Fair Market Value (as determined pursuant to Section 1.3) of a full Share.

 

2.            ANTI-DILUTION
PROVISIONS; ADJUSTMENT IN WARRANT AMOUNT AND WARRANT EXERCISE PRICE. The Warrant Exercise Price and Warrant Amount shall be
subject to adjustment from time to time as provided in this Section 2.

 

2.1       Dividends,
Subdivisions and Combinations. If Company, at any time and from time to time, (i) takes a record of the holders of its
Common Stock for the purpose of entitling them to receive, or otherwise declares or distributes, a dividend payable in, or other
distribution of, additional shares of Common Stock or Common Stock Equivalents, (ii) splits or subdivides its outstanding
shares of Common Stock into a greater number of shares of Common Stock or Common Stock Equivalents, or (iii) combines its
outstanding shares of Common Stock into a smaller number of shares of Common Stock or Common Stock Equivalents, then, in each such
case, (a) the Warrant Amount shall be adjusted to equal the product of (x) the Warrant Amount in effect immediately prior to the
adjustment multiplied by (y) a fraction, the numerator of which is equal to the number of shares of Common Stock outstanding immediately
after such adjustment and the denominator of which is equal to the number of shares of Common Stock outstanding immediately prior
to the adjustment, and (b) the Warrant Exercise Price shall be adjusted pursuant to Section 2.2 .

 

2.2       Adjustment
of Warrant Exercise Price. Upon any adjustment of the Warrant Amount as provided in Sections 2.1, the Warrant Exercise
Price shall be adjusted to be equal to the product of (i) the Warrant Exercise Price in effect immediately prior to such adjustment
multiplied by (ii) the quotient of the Warrant Amount in effect immediately prior to such adjustment divided by the Warrant
Amount in effect immediately after such adjustment.

 

2.3       Determination
of Adjustments. Upon any event that shall require an adjustment pursuant to this Section 2, Company shall promptly
calculate such adjustment in accordance with the terms of this Warrant and prepare a certificate setting forth, in reasonable detail,
such adjustment, the method of calculation thereof and the facts upon which such adjustment is based.

 

3.       CERTAIN
AGREEMENTS. Company hereby covenants and agrees as follows:

 

3.1       Shares
to be Fully Paid. All Shares shall, upon issuance in accordance with the terms of this Warrant, be duly and validly
issued, fully paid and non-assessable.

 

3.2       Reservation
of Shares. Until the Expiration Date, Company at all times shall have authorized, and reserved for the purpose of issuance
upon exercise of this Warrant, a sufficient number of shares of Common Stock to provide for the exercise of this Warrant in full.

 

    
Signature Page to Common Stock Purchase Warrant

     

    

 

3.3       Successors
and Assigns. This Warrant shall be binding upon any entity succeeding to Company by merger, consolidation, or acquisition
of all or substantially all Company’s assets or all or substantially all of Company’s outstanding capital stock or
otherwise.

 

4.            TRANSFER
AND REPLACEMENT OF WARRANT.

 

4.1       Restriction
on Transfer. Subject to this Section 4.1, this Warrant and the rights granted to Holder are transferable and assignable,
in whole or in part, upon surrender of this Warrant, together with a properly executed assignment in substantially the form attached
as Appendix 2, at the office or agency of Company referred to in Section 4.4. Nothing in this Warrant shall prohibit
Holder from assigning, delegating or transferring this Warrant and Holder’s rights and obligations under this Warrant to
an Affiliate of Holder. Otherwise, Holder may not assign, delegate or otherwise transfer (whether by operation of law, by contract
or otherwise) its rights and obligations under this Warrant, or any portion hereof or thereof, to any Person whose principal business
is providing integrated healthcare services or who otherwise is a competitor of Company as determined reasonably and in good faith
by the Board of Directors. Until due presentment for registration of transfer on the books of Company, Company may treat the registered
holder hereof as the owner of this Warrant and Holder for all purposes, and Company shall not be affected by any notice to the
contrary. Notwithstanding anything herein contained to the contrary, none of the Warrants may be transferred separately from the
Shares of Series B Preferred Stock to which they relate (1-for-1).

 

4.2       Replacement
of Warrant. Upon receipt of evidence reasonably satisfactory to Company of the loss, theft, destruction or mutilation of this
Warrant and, in the case of any such loss, theft or destruction, upon delivery of an indemnity agreement reasonably satisfactory
in form and amount to Company, or, in the case of any such mutilation, upon surrender and cancellation of this Warrant, Company,
at its expense, shall execute and deliver to Holder, in lieu thereof, a new Warrant of like tenor.

 

4.3       Cancellation;
Payment of Expenses. Upon the surrender of this Warrant in connection with any transfer, exchange or replacement, this Warrant
shall be promptly canceled by Company. Company shall pay all taxes (other than securities transfer taxes) and all other expenses
(other than legal expenses, if any, incurred by Holder or transferees) and charges payable in connection with the preparation,
execution, and delivery of a new Warrant issued to Holder or transferees, as applicable.

 

4.4       Register.
Company shall maintain, at its principal executive offices (or such other office or agency of Company as it may designated by notice
to Holder), a register for this Warrant, in which Company shall record the name and address of the Person in whose name this Warrant
has been issued, as well as the name and address of each transferee and each prior owner of this Warrant.

 

5.             MISCELLANEOUS.

 

5.1       Term.
This Warrant is exercisable or convertible in whole or in part at any time and from time to time before or on the Expiration Date
on no less than thirty-one (31) days’ prior written notice to the Company (unless the Company otherwise agrees to a shorter
notice period).

 

    
Signature Page to Common Stock Purchase Warrant

     

    

 

5.2       Notices.
All demands, notices, approvals, consents, requests, and other communications hereunder shall be in writing and shall be deemed
to have been given when the writing is delivered, if given or delivered by hand, overnight delivery service or facsimile transmitter
(with confirmed receipt), or five (5) days after being mailed, if mailed, by first class, registered or certified mail, postage
prepaid, to the address or telecopy number set forth below. If any time period for giving notice or taking action hereunder expires
on a day that is not a Trading Day, the time period shall automatically be extended to the Trading Day immediately following such
day. Such notices, demands, requests, consents and other communications shall be sent to the following Persons at the following
addresses:

 

if to Company:

 

Apollo Medical
Holdings, Inc.

700 N. Brand
Blvd., Suite 1400

Glendale,
California 91203

Attention:
Warren Hosseinion, M.D., Chief Executive Officer

Telephone:
(818) 396-8050

Fax: (818)
844-3888

 

if to Holder:

 

Liviu Chindris, M.D.

902 Flintridge Ave.

La Canada, CA 91011

Telephone:
626-818-7042

 

Company or Holder
may, by notice given hereunder, designate any further or different addresses or telecopy numbers to which subsequent demands, notices,
approvals, consents, requests or other communications shall be sent or persons to whose attention the same shall be directed.

 

5.3       Waivers.
The rights and remedies provided for herein are cumulative and not exclusive of any right or remedy that may be available to Holder
whether at law, in equity, or otherwise. No delay, forbearance, or neglect by Holder, whether in one or more instances, in the
exercise of any right, power, privilege, or remedy hereunder or in the enforcement of any term or condition of this Warrant shall
constitute or be construed as a waiver thereof. No waiver of any provision hereof, or consent required hereunder, or any consent
or departure from this Warrant, shall be valid or binding unless expressly and affirmatively made in writing and duly executed
by Holder. No waiver shall constitute or be construed as a continuing waiver or a waiver in respect of any subsequent breach, either
of similar or different nature, unless expressly so stated in such writing.

 

5.4       Specific
Enforcement. The parties hereto agree that irreparable damage would occur in the event that any of the provisions of this Warrant
were not performed in accordance with their specific intent or were otherwise breached. It is accordingly agreed that the parties
shall be entitled to an injunction or injunctions to prevent or cure breaches of the provisions of this Warrant and to enforce
specifically the terms and provisions hereof, in addition to any other remedy to which they may be entitled by law or equity.

  

    
Signature Page to Common Stock Purchase Warrant

     

    

 

5.5       Counterparts.
This Warrant may be executed simultaneously in two or more counterparts, any one of which need not contain the signatures of more
than one party, but all such counterparts taken together shall constitute one and the same Warrant. Counterparts may be delivered
via facsimile, electronic mail (including pdf) or other transmission method and any counterpart so delivered shall be deemed to
have been duly and validly delivered and be valid and effective for all purposes.

 

5.6       Governing
Law. This Warrant shall be governed by and construed in accordance with the laws of the State of California, without giving
effect to any choice or conflict of law provision or rule (whether of the State of California or any other jurisdiction) that would
cause the application of the laws of any jurisdiction other than the State of California. Holder agrees that all legal proceedings
concerning the interpretations, enforcement and defense of the transactions contemplated by this Warrant (whether brought against
Holder, the Company or their respective affiliates, directors, officers, shareholders, partners, members, employees or agents)
shall be commenced exclusively in the state and federal courts sitting in the County of Los Angeles. Each party hereby irrevocably
submits to the exclusive jurisdiction of the state and federal courts sitting in the County of Los Angeles for the adjudication
of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby
irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to
the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient venue for such proceeding.

 

5.7       Amendment.
This Warrant may be amended, modified, or supplemented only pursuant to a written instrument making specific reference to this
Warrant and signed by Company and Holder.

 

5.8       Severability.
Whenever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable
law, but if any provision of this Warrant is held to be invalid or unenforceable in any respect, such invalidity or unenforceability
shall not render invalid or unenforceable any other provision of this Warrant.

 

5.9       Descriptive
Headings; No Strict Construction. The descriptive headings of this Warrant are inserted for convenience only and do not constitute
a substantive part of this Warrant. The parties to this Warrant have participated jointly in the negotiation and drafting of this
Warrant. If an ambiguity or question of intent or interpretation arises, this Warrant shall be construed as if drafted jointly
by the parties hereto, and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship
of any of the provisions of this

 

    
Signature Page to Common Stock Purchase Warrant

     

    

 

Warrant. The parties
agree that prior drafts of this Warrant shall be deemed not to provide any evidence as to the meaning of any provision hereof or
the intention of the parties hereto with respect to this Warrant.

 

IN WITNESS WHEREOF,
the parties have duly executed and delivered this Common Stock Purchase Warrant by their duly authorized representatives as of
the date first above written.

 

 

	 	COMPANY:	 
	 	 	 
	 	APOLLO MEDICAL HOLDINGS, INC.	 
	 	 	 
	 	 	 
	 	By:	/s/ Warren Hosseinion, M.D.	 
	 	Name:	Warren Hosseinion, M.D.	 
	 	Title:	Chief Executive Officer	 
	 	 	 	 
	 	 	 	 
	 	HOLDER:	 
	 	 	 	 
	 	 	 	 
	 	/s/ Liviu Chindris,
    M.D.	 
	 	Name:	Liviu Chindris, M.D.	 

  

    
Signature Page to Common Stock Purchase Warrant

     

    

 

APPENDIX 1

 

FORM OF NOTICE
OF EXERCISE

 

TO: APOLLO MEDICAL
HOLDINGS, INC.

 

1.       The
undersigned hereby elects to purchase ________ Shares of the Common Stock of Apollo Medical Holdings, Inc. pursuant to the terms
of the attached Common Stock Purchase Warrant (the “Warrant”) issued to the undersigned (or the undersigned’s
predecessor or assignor), and shall tender payment of the exercise price in full in accordance with the terms of the Warrant.

 

2.       Payment
shall take the form of (check applicable box):

 

		 ̈	in lawful money of the United States; or

 

		 ̈	the cancellation of such number of Shares as is necessary,
in accordance with the formula set forth in Section 1.2 of the Warrant, to exercise the Warrant with respect to the maximum
number of Shares purchasable pursuant to the cashless exercise procedure set forth in Section 1.2 of the Warrant.

 

3.       Please
issue a certificate or certificates (or, if applicable, Book-Entry Shares) representing said Shares in the name of the undersigned
or in such other name as is specified below:

 

The
Shares shall be delivered by physical delivery of a certificate (or, if applicable, Book-Entry Shares) to:

 

 

 

[SIGNATURE OF HOLDER]

 

Name of Holder:

Signature of Authorized
Signatory of Holder:

Name of Authorized
Signatory:

Title of Authorized
Signatory:

Date:

 

Date of exercise
under Section 1.1 of the Warrant or date of exercise of conversion right under Section 1.2 of the Warrant is the
date this Notice is deemed effectively given under Section 5.2 of this Warrant.

 

     

     

    

 

APPENDIX 2

 

ASSIGNMENT FORM

 

(To Assign the
foregoing Warrant, execute

this form and supply
required information.

Do not use this
form to exercise the Warrant.)

 

FOR VALUE RECEIVED,

 

(check
first box OR fill in number of Shares in second box)

 

[___] all
of the Warrant

 

OR

 

[__________]
shares of the foregoing Warrant

 

and all rights evidenced
thereby are hereby assigned to:

 

_________________________________________
whose address is _____________________ _____________________________________________________________________________.

 

	 	Dated:   ____________________, _________
	 	 	 
	 	Holder’s Signature:	 
	 	 	 
	 	Holder’s Address:EXHIBIT 10.1

 

Exhibit
A

 

PROMISSORY
NOTE

(Term Loan)

 

	$400,000.00	 	Glendale,
    California

    November 17, 2016

        

        FOR
VALUE RECEIVED the undersigned Apollo Medical Management, Inc., a California corporation (“Maker”) promises
to pay to the order of Liviu Chindris, M.D. (“Payee”), on or before February
18, 2017 (the “Maturity Date”), the principal sum of Four Hundred Thousand Dollars and No Cents ($400,000.00) (the
“Loan”), together with interest prior to the Maturity Date, upon the terms set forth in this Promissory Note (this
“Note”).

 

        1.        
Interest.    Interest shall accrue on any principal balance outstanding hereunder from and including
the date hereof at a rate per annum equal to twelve percent (12%) per annum. All computations of interest and fees under this
Note shall be made on the basis of a year of three hundred sixty-five (365) days and calculated for the actual days elapsed.

 

        2.        
Repayment. Maker will repay this Loan as to outstanding principal and accrued interest, in full, on the Maturity Date.
In any and all events, the entire remaining balance of this Note is due and payable on the Maturity Date. Acceptance by Payee
of any payment which is less than payment in full of all amounts due and owing at such time shall not constitute a waiver of Payee’s
right to receive payment in full at such or any other time.

 

        
Each payment of principal and interest due under this Note shall be made by Maker to Payee at its offices. All sums paid on this
Note shall be applied first to interest accrued to the date of payment, and then to principal. Each payment due under this Note
shall be made without set-off or counterclaim in immediately available funds on a Business Day not later than 5:00 p.m. California
local time. All sums received after such time shall be deemed received on the next Business Day. If any payment of principal or
interest under this Note is payable on a day other than a Business Day, the maturity of such installment shall be extended to
the next succeeding Business Day, and interest shall be payable during such extension of maturity.

 

        
All sums payable hereunder will be payable with attorneys’ fees and costs of collection and without relief from valuation
and appraisement laws. Maker and all endorsers hereof hereby severally waive presentment for payment, protest, notice of protest,
notice of non-payment and all other notices or demands in connection with the delivery, acceptance, performance, default, endorsement
or guaranty of this Note, notice of loans made, credit extended, collateral received or delivered, or other action taken in reliance
hereon and all other demands and notices of any description. Further, Maker and all endorsers hereof hereby severally consent
to extensions of time with respect to sums payable hereunder and any collateral for this indebtedness. Maker consents to any extension
or postponement of the time of payment or any other indulgence to any substitution, exchange or release of or failure to perfect
any security interest in such collateral, to the adding or release of any party or person primarily or secondarily liable, to
the acceptance of partial payment thereon, and the settlement, compromise or adjustment of any thereof, all in such manner and
at such time as Payee may deem advisable.

 

        3.        
Prepayment. Maker may prepay all or any part of the principal balance of this Note at any time without premium or penalty.

 

        4.        
Events of Default.

 

        (a)       The
occurrence of any of the following events or conditions shall constitute an event of default hereunder (each, an "Event
of Default"):

 

                   (i)
Maker shall fail to make when due any payments on this Note;

 

     1

     

    

 

                   (ii)
any breach of a representation or warranty of Maker contained in this Note which remains uncured after fifteen (15) business days
from the written notice thereof and which breach shall have a material adverse effect on (A) the financial condition of Maker
or (B) the ability of Maker to perform under its obligations this Note;

 

                   (iii)
any default in the material observance or performance by Maker of any covenant or agreement contained in this Note which default
remains uncured after fifteen (15) business days after written notice thereof and which default shall have a material adverse
effect on (A) the financial condition of Maker or (B) the ability of Maker to perform under its obligations this Note;

 

                   (iv)
Maker shall: (A) file a voluntary petition or assignment in bankruptcy or a voluntary petition or assignment or answer seeking
liquidation, reorganization, arrangement, readjustment of his debts, or any other relief under the Bankruptcy Reform Act of 1978,
as amended (the "Bankruptcy Code"), or under any other act or law pertaining to insolvency or debtor relief, whether
State, Federal, or foreign, now or hereafter existing; (B) enter into any agreement indicating consent to, approval of, or acquiescence
in, any such petition or proceeding; (C) apply for or permit the appointment, by consent or acquiescence, of a receiver, custodian
or trustee of all or a substantial part of his property; (D) make an assignment for the benefit of creditors; (E) be unable or
shall fail to pay his debts generally as such debts become due; and

 

                   (v)
there occurs (A) a filing or issuance against Maker of an involuntary petition in bankruptcy or seeking liquidation, reorganization,
arrangement, readjustment of its debts or any other relief under the Bankruptcy Code, or under any other act or law pertaining
to insolvency or debtor relief, whether State, Federal or foreign, now or hereafter existing; (B) the involuntary appointment
of a receiver, liquidator, custodian or trustee of Maker or for all or a substantial part of his property; or (C) the issuance
of a warrant of attachment, execution or similar process against all or any substantial part of the property of Maker and such
shall not have been discharged (or provision shall not have been made for such discharge), or stay of execution thereof shall
not have been procured, within sixty (60) days from the date of entry thereof.

 

        (b)
Acceleration. If an Event of Default occurs under Section 4(a), then the outstanding principal and interest and any other
customary legal and business collection costs under this Note shall automatically become immediately due and payable, without
presentment, demand, protest or notice of any kind, all of which are expressly waived. If any other Event of Default occurs and
is continuing, the holder, by written notice to the Maker, may declare the outstanding principal and interest under this Note
to be immediately due and payable.

 

        (c)
Remedies.

 

                   (i)
Upon the occurrence of an Event of Default, the holder may avail itself of any legal or equitable rights which the Holder may
have at law or in equity or under this Note, including, but not limited to, the right to accelerate the indebtedness due under
this Note as described in Section 4(b). The remedies of the holder as provided herein shall be distinct and cumulative, and may
be pursued singly, successively or together, at the sole discretion of the holder, and may be exercised as often as occasion therefor
shall arise.

 

                   (ii)
Forbearance by holder to exercise its rights with respect to any failure or breach by Maker shall not constitute a waiver of the
right as to the same or any subsequent failure or breach, and no single or partial exercise of any right or remedy shall preclude
other or further exercise of the same or any other right or remedy. The holder shall have no duty to exercise any or all of the
rights and remedies herein provided or contemplated. The acceptance by the holder of any payment hereunder that is less than payment
in full of all amounts due and payable at the time of such payment shall not constitute a waiver of the right to exercise any
of the foregoing rights or remedies at that time, or nullify any prior exercise of any such rights or remedies without the express
written consent of the holder.

 

        (d)
Default Rate. After maturity (by acceleration or otherwise) the unpaid balance (both principal and unpaid pre-maturity
interest) shall bear interest at a default rate equal to the lesser of (a) Fifteen percent (15%) over the rate of interest in
effect immediately prior to maturity or (ii) the then maximum legal rate allowed under the laws of the State of California.

 

     2

     

    

 

        5.        
Notices. All notices to be given pursuant to this Note will be sufficient if given by personal service, or by guaranteed
overnight delivery service, or by postage prepaid mailing by certified or registered mail with return receipt requested, to the
parties as set forth below, or to such other address as a party may request by notice given pursuant to this Section. Any time
period provided in the giving of any notice hereunder shall commence upon the date of personal service, the day after delivery
to the guaranteed overnight delivery service, or three (3) days after mailing certified or registered mail. However, any failure
to give notice in accordance with the terms of this Section will not invalidate such notice if such notice was in fact in writing
and actually received by the party to whom it was directed.

 

	 	MAKER:	Apollo
                           Medical Management, Inc.

                           700 North Brand Avenue

                           Suite 1400

        Glendale,
        California 91203

        Attention:  Warren Hosseinion, M.D.

	 	PAYEE:	Liviue
    Chindris, M.D.

 

        6.        
Governing Law. This Note and all rights and obligations hereunder, including matters of construction, validity and performance,
will be governed by the laws of the State of California without regard to principles of conflicts of law. Whenever possible, each
provision of this Note will be interpreted in such a manner as to be effective and valid upon applicable law, but if any provision
of this Note will be prohibited by or invalid under applicable law, such provision will be ineffective only to the extent of such
prohibition without invalidating the remainder of such provision or the remaining provisions of this Note.

 

        7.        Waiver.
Each endorser and any other party liable on this Note severally waives demand, presentment, notice of dishonor and protest, and
consents to any extension or postponement of time of its payment without limit as to the number or period, to the addition of
any party, and to the release or discharge of, or suspension of any rights and remedies against, any person who may be liable
for the payment of this Note. No delay on the part of Payee in the exercise of any right or remedy shall operate as a waiver.
No single or partial exercise by Payee of any right or remedy shall preclude any other future exercise of it or the exercise of
any other right or remedy. No waiver or indulgence by Payee of any default shall be effective unless in writing and signed by
Payee, nor shall a waiver on one occasion be construed as a bar to or waiver of that right on any future occasion.

 

        8.        
Miscellaneous. This Note shall be binding on Maker and Maker’s successors, and shall inure to the benefit of Payee,
its successors and assigns. Any reference to Payee shall include any holder of this Note. Section headings are for convenience
of reference only and shall not affect the interpretation of this Note. This Note embodies the entire agreement between Maker
and Payee regarding the terms of the Loan evidenced by this Note and supersede all oral statements and prior writings relating
to the Loan.

 

        
IN WITNESS WHEREOF, Maker has executed this Promissory Note this 17 day of November, 2016.

 

	 	APOLLO MEDICAL MANAGEMENT. INC.
	 	 	 
	 	 	 
	 	By:	/s/ Warren Hosseinion,
    M.D.
	 	 	Warren Hosseinion,
    M.D.
	 	 	Chief Executive
    Officer

 

     3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00266-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00266-of-00352.parquet"}]]